Tower Research Capital (TRC)’s Burning Rock Biotech BNR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,242
Closed -$10.4K – 5912
2026
Q2
$10.4K Buy
1,242
+1,214
+4,336% +$17.2K ﹤0.01% 3985
2026
Q1
$452 Buy
+28
New +$733 ﹤0.01% 4869
2025
Q1
– Sell
-192
Closed -$1.3K – 5222
2024
Q4
$1.3K Buy
192
+14
+8% +$64 ﹤0.01% 5053
2024
Q3
$582 Sell
178
-83
-32% -$458 ﹤0.01% 5306
2024
Q2
$1.64K Buy
+261
New +$1.99K ﹤0.01% 5117
2023
Q4
– Sell
-17
Closed -$169 – 5929
2023
Q3
$169 Sell
17
-68
-80% -$1.06K ﹤0.01% 5676
2023
Q2
$1.82K Buy
+85
New +$2.26K ﹤0.01% 5308
2023
Q1
– Sell
-1,237
Closed -$28K – 5822
2022
Q4
$28K Buy
1,237
+698
+129% +$15.9K ﹤0.01% 2801
2022
Q3
$13K Sell
539
-34
-6% -$1.1K ﹤0.01% 4257
2022
Q2
$16K Buy
573
+328
+134% +$14.6K ﹤0.01% 3999
2022
Q1
$23K Buy
245
+222
+965% +$19.3K ﹤0.01% 3387
2021
Q4
$2K Buy
+23
New +$3.15K ﹤0.01% 5599
2021
Q3
– Sell
-7
Closed -$2K – 5772
2021
Q2
$2K Buy
+7
New +$2.07K ﹤0.01% 5019

Other funds holding BNR

Tower Research Capital (TRC)'s BNR Position: Q3 2026 in Review

Tower Research Capital (TRC) sold out of Burning Rock Biotech (BNR) in Q3 2026, closing a stake of 1,242 shares — an estimated $10.4K sold.

Tower Research Capital (TRC) first reported a position in BNR in Q2 2021 and held it in 13 quarters. The position peaked at $28K in Q4 2022. 17 funds tracked by Wall St. Rank hold BNR as of Q3 2026.

  • Tower Research Capital (TRC) reported no remaining Burning Rock Biotech position as of Q3 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,242 Burning Rock Biotech shares in Q3 2026, an estimated $10.4K.
  • Tower Research Capital (TRC) first reported a position in Burning Rock Biotech in Q2 2021 and held it in 13 quarters.
  • Tower Research Capital (TRC)'s Burning Rock Biotech position peaked at $28K in Q4 2022.
  • 17 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.